Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics

In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review presents prior and current advances in the development of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like peptide-1 receptor. The revie...

Descripción completa

Detalles Bibliográficos
Autores principales: Velikyan, Irina, Eriksson, Olof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929622/
https://www.ncbi.nlm.nih.gov/pubmed/31903131
http://dx.doi.org/10.7150/thno.38366
_version_ 1783482738095947776
author Velikyan, Irina
Eriksson, Olof
author_facet Velikyan, Irina
Eriksson, Olof
author_sort Velikyan, Irina
collection PubMed
description In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review presents prior and current advances in the development of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like peptide-1 receptor. The review covers chemistry, preclinical, and clinical evaluation. Such critical aspects as structure-activity-relationship, stability, physiological potency, kidney uptake, and dosimetry are discussed.
format Online
Article
Text
id pubmed-6929622
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-69296222020-01-04 Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics Velikyan, Irina Eriksson, Olof Theranostics Review In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review presents prior and current advances in the development of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like peptide-1 receptor. The review covers chemistry, preclinical, and clinical evaluation. Such critical aspects as structure-activity-relationship, stability, physiological potency, kidney uptake, and dosimetry are discussed. Ivyspring International Publisher 2020-01-01 /pmc/articles/PMC6929622/ /pubmed/31903131 http://dx.doi.org/10.7150/thno.38366 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Velikyan, Irina
Eriksson, Olof
Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics
title Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics
title_full Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics
title_fullStr Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics
title_full_unstemmed Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics
title_short Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics
title_sort advances in glp-1 receptor targeting radiolabeled agent development and prospective of theranostics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929622/
https://www.ncbi.nlm.nih.gov/pubmed/31903131
http://dx.doi.org/10.7150/thno.38366
work_keys_str_mv AT velikyanirina advancesinglp1receptortargetingradiolabeledagentdevelopmentandprospectiveoftheranostics
AT erikssonolof advancesinglp1receptortargetingradiolabeledagentdevelopmentandprospectiveoftheranostics

Ejemplares similares